Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 8/20 | 0.44 |
| ▸ | F13A1 | P00488 | 6/20 | 0.44 |
| ▸ | TGM1 | P22735 | 5/20 | 0.44 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 4/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822929 | 0.81 | TGM2 (0.44) | TGM2F13A1TGM1TGM3NR1H2 | |
| SCHEMBL2823128 | 0.73 | TGM2 (0.46) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL13239816 | 0.72 | TGM2 (0.59) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL4274049 | 0.72 | STS (0.60) | TGM2F13A1TGM1TGM3STS | |
| SCHEMBL2822128 | 0.72 | CNR1 (0.50) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL20451456 | 0.72 | TGM2 (0.49) | TGM2F13A1TGM1TGM3ATM | |
| SCHEMBL25003057 | 0.71 | NR1H2 (0.47) | NR1H2NR1H3MAPTSTSGPR119 | |
| SCHEMBL2820911 | 0.71 | TGM2 (0.49) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL29060789 | 0.71 | MAPT (0.73) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL2224488 | 0.70 | TGM2 (0.60) | TGM2F13A1TGM1TGM3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1849469-B1 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC (US) | 2010-10-27 | — | — | EP | disclosed |
| EP-1849469-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | Actimis Pharmaceuticals, Inc., (US) | 2007-10-31 | — | — | EP | disclosed |